Drugs in Dev. Cardiology/Vascular Diseases
Phase IV
Ireland 
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : MedStar Health Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REDUCE-IT, global cardiovascular outcome study designed to assess cardioprotective efficacy and safety of VASCEPA (icosapent ethyl), a unique form of eicosapentaenoic acid, as an add-on to statin therapy in reducing major cardiovascular event in a high-r...
Product Name : Vascepa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2022
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : MedStar Health Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vascepa (Icosapent ethyl) 4 g/day significantly reduced total primary endpoints by 32%, and trended toward a 22% reduction in first events, in patients with PAD.
Product Name : Vascepa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 16, 2021
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The investigators concluded that, “Icosapent ethyl 4 g/day significantly reduced total (first and subsequent) primary endpoints by 32%, and trended toward a 22% reduction in first events, in patients with PAD.
Product Name : Vascepa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 15, 2021
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VASCEPA® (icosapent ethyl) demonstrated significant, 17% regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months.
Product Name : Vascepa
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 17, 2021
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
